Meridigen‑COPD
Chronic Obstructive Pulmonary Disease
PreclinicalActive
Key Facts
About Meridigen Biotech
Taiwanese MSC‑focused biotech developing neuro‑vascular and pulmonary cell therapies.
View full company profileTherapeutic Areas
Other Chronic Obstructive Pulmonary Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Technegas® for COPD | Cyclomedica | Phase 2 |
| Emeramide for COPD | EmeraMed | Phase 2 |
| Autologous Stem Cell Therapy for COPD | STEMGENICS | Phase 2 |
| Novel Anti-inflammatory for COPD | Shenzhen Salubris Pharmaceuticals | Phase I/II |
| F528 | Gyre Therapeutics | Not Specified |